If you are wondering whether CRISPR Therapeutics at around US$50.17 offers fair value or a potential mispricing, you are not alone.
The stock has recently been choppy, with a 7 day return of 6.6% decline, a 30 day return of 9.0% decline, and a year to date move of 6.7% decline, although the 1 year return stands at 18.8% while the 3 year and 5 year returns are 6.0% decline and 68.7% decline respectively.
Recent attention on gene editing and CRISPR based therapies has kept the company in the conversation for investors who follow high risk, high reward biotech names. This context helps frame the mixed return profile, where long term holders have experienced large drawdowns while more recent periods have looked different.
